CCH Holdings (CCHH) sees co-CEO and directors exit, appoints two replacements

Rhea-AI Filing Summary

CCH Holdings Ltd reported significant board and management changes in early August 2026. Effective August 5, 2026, independent director Wu Wai Kong resigned, stepping down as chair of the Compensation Committee and member of the Nominating and Corporate Governance and Audit Committees. Effective August 7, 2026, director and co-chief executive officer Mhlengi Prevail Mafu and director Chung Wai Wong also resigned; Wong concurrently left the same board committees. The company stated that none of these resignations resulted from any disagreement on operations, policies, or practices.

On August 7, 2026, the board appointed Hsu Hui Chen as director and co-chief executive officer and Lim Fei Fern as independent director. Lim becomes chair of the Compensation Committee and a member of the Audit and Nominating and Corporate Governance Committees. The appointments have no specific term and may be terminated at any time. The company highlights the new directors’ extensive procurement, finance, and internal-control experience and notes they have no family relationships with existing leadership and no transactions requiring disclosure under Item 404(a) of Regulation S-K.

Positive

• None.

Negative

• Leadership turnover: three directors, including a co-chief executive officer, resigned effective August 5–7, 2026, creating simultaneous changes in board membership and key committee leadership.

Key Figures

Effective date of first resignation: August 5, 2026 Effective date of further resignations and appointments: August 7, 2026 Number of directors resigning: 3 directors +1 more

4 metrics

Effective date of first resignation August 5, 2026 Resignation of independent director Wu Wai Kong from the board and committees

Effective date of further resignations and appointments August 7, 2026 Resignations of Mhlengi Prevail Mafu and Chung Wai Wong and appointment of two new directors

Number of directors resigning 3 directors Wu Wai Kong, Mhlengi Prevail Mafu and Chung Wai Wong resigned from board roles

Number of new directors appointed 2 directors Board appointed Ms. Hsu Hui Chen and Ms. Lim Fei Fern on August 7, 2026

Key Terms

independent director, Compensation Committee, Nominating and Corporate Governance Committee, Item 404(a) of Regulation S-K

4 terms

independent director regulatory

"Ms. Lim Fei Fern was appointed as the independent director, as well as the chairperson"

An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.

Compensation Committee regulatory

"chairperson of the Compensation Committee, a member of the Audit Committee"

A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.

Nominating and Corporate Governance Committee regulatory

"a member of the Nominating and Corporate Governance Committee of the Company"

A nominating and corporate governance committee is a group within a company's board of directors responsible for selecting and recommending individuals to serve as company leaders, such as directors or executives. They also develop and oversee policies to ensure the company is run fairly, ethically, and transparently. This committee matters to investors because it helps ensure the company is well-managed and guided by qualified, responsible leadership.

Item 404(a) of Regulation S-K regulatory

"would require disclosure under Item 404(a) of Regulation S-K"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 08/07/2026 - 06:46 AM Accepted by SEC EDGAR 08/07/2026 - 06:45 AM Learn about SEC filing dates

FAQ

Which CCHH directors and officers resigned in August 2026?

Three individuals resigned from CCH Holdings Ltd. Independent director Wu Wai Kong resigned effective August 5, 2026. On August 7, 2026, Mhlengi Prevail Mafu, a director and co-chief executive officer, and director Chung Wai Wong also resigned from their board and committee roles.

Who was appointed to new leadership roles at CCHH after the resignations?

The board appointed Hsu Hui Chen as director and co-chief executive officer and Lim Fei Fern as independent director on August 7, 2026. Lim also became chair of the Compensation Committee and a member of the Audit and Nominating and Corporate Governance Committees.

Did the August 2026 resignations at CCHH involve disagreements with the company?

The company stated that none of the resignations by Wu Wai Kong, Mhlengi Prevail Mafu, or Chung Wai Wong resulted from any disagreement with CCH Holdings Ltd on its operations, policies, or practices, indicating cooperative separations rather than disclosed governance disputes.

What board committees will new CCHH director Lim Fei Fern serve on?

Lim Fei Fern was appointed independent director, chairperson of the Compensation Committee, and a member of the Audit Committee and the Nominating and Corporate Governance Committee, effective August 7, 2026, assuming key oversight responsibilities previously held by departing directors.

What experience does new CCHH co-CEO Hsu Hui Chen bring?

Hsu Hui Chen has extensive experience in global sourcing, procurement strategy, vendor management, and contract negotiation, including senior roles at Parexel International from 2008 to 2025. Her background emphasizes supplier performance, risk mitigation, cost optimization, and managing complex medical equipment and logistics categories.

Do the new CCHH directors have related-party ties or reportable transactions?

CCH Holdings Ltd reported that Hsu Hui Chen and Lim Fei Fern have no family relationship with any company director or executive officer and have not engaged in transactions with the company in the past two years requiring disclosure under Item 404(a) of Regulation S-K.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

SECURITIES EXCHANGE ACT OF 1934

For the month of August 2026

Commission File Number 001-42864

CCH Holdings Ltd

(Exact name of registrant as specified in its charter)

No. 1, Jalan Perda Jaya, Kawasan Perniagaan Perda Jaya, 14000

Bukit Mertajam, Pulau Pinang, Malaysia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒         Form 40-F ☐

Appointment and Departure of Directors and Officers

Resignation of Directors and Officers

Effective as of August 5, 2026, Wu Wai Kong resigned as an independent director, the chairperson of the Compensation Committee, a member of the Nominating and Corporate Governance Committee and a member of the Audit Committee of the Company. Effective as of August 7, 2026, Mhlengi Prevail Mafu resigned as a director and co-chief executive officer of the Company. Effective as of August 7, 2026, Chung Wai Wong resigned as a director and a member of Nominating and Corporate Governance Committee, a member of Audit Committee and a member of Compensation Committee. None of these resignations resulted from any disagreement with the Company on any matter relating to its operations, policies, or practices. The Board accepted the resignations of Wu Wai Kong, Mhlengi Prevail Mafu and Chung Wai Wong from their respective positions of the Company.

Appointment of Directors and Officers

Effective August 7, 2026 the Board appointed Ms. Hsu Hui Chen and Ms. Lim Fei Fern (the “New Directors”) in lieu of Mhlengi Prevail Mafu and Wu Wai Kong, respectively. Ms. Hsu Hui Chen was appointed as the director and co-chief executive officer of the Company, effective from August 7, 2026. Ms. Lim Fei Fern was appointed as the independent director, as well as the chairperson of the Compensation Committee, a member of the Audit Committee and a member of the Nominating and Corporate Governance Committee of the Company, effective from August 7, 2026. The appointment has no specific term and can be terminated by either the New Directors or the Company at any time without advance notice. The biographical information of the New Directors is set forth below.

Ms. Hsu Hui Chen has extensive experience in global sourcing, procurement strategy, vendor management, and contract negotiation across various industries, including clinical trials, electrical, and electronic sectors. She served as Global Category Senior Manager / Strategic Procurement at Parexel International from February 2020 to September 2025, where she oversaw global procurement strategies for medical equipment, ancillary supplies, customs brokerage, and courier categories, while driving cost optimization and vendor playbook development. Prior to that, Ms. Hsu held various management and strategic sourcing positions at Parexel International from October 2008 to February 2020, including Global Vendor Relationship Manager and Global Category Sourcing Manager, where she managed supplier performance, risk mitigation, and cross-functional team leadership. Ms. Hsu specializes in developing holistic supply base strategies, executing major service agreements, and optimizing total cost of ownership. Ms. Hsu holds a bachelor’s degree in Business Administration from National Taiwan University.

Ms. Lim Fei Fern is a seasoned finance and accounting professional specializing in financial management, operational cost optimization, and internal controls. She has served as the Finance Manager at SRX Malaysia Sdn Bhd since September 2015, where she leads the finance team in managing operational financial needs, financial reporting, cash management, e-invoicing implementation, and post-acquisition finance integration. Prior to that, Ms. Lim served as the Accounting Manager at ASM Technology (M) Sdn Bhd from March 2014 to September 2015, and as a Management Accountant at Kerry Ingredients (M) Sdn Bhd from August 2012 to March 2014, focusing on cost accounting, inventory control, and operational variance analysis. Prior to 2012, she served as an Accountant at Tridonic Malaysia Sdn Bhd (2011–2012) and held accounting roles at Beyonics Technology (Senai) Sdn Bhd (2006–2011), accumulating extensive experience in AP/AR/GL management, transfer pricing, forex compliance, and fixed assets management. Ms. Lim’s expertise lies in establishing robust internal controls, optimizing working capital, and ensuring regulatory compliance in cross-border transactions. Ms. Lim holds a bachelor’s degree in Commerce (Accounting & Finance) from Curtin University of Technology, Australia, and is a certified member of CPA Australia and the Malaysian Institute of Accountants.

Ms. Hsu Hui Chen and Ms. Lim Fei Fern do not have any family relationship with any director or executive officer of the Company. They have not been involved in any transaction with the Company during the past two years that would require disclosure under Item 404(a) of Regulation S-K. 

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: August 7, 2026	CCH HOLDINGS LTD
	By:	/s/ Goh Kok E
	Name:	Goh Kok E
	Title:	Chairman and Chief Executive Officer and Chief Operating Officer

2